Nuveen
STLN

Nuveen’s Starling Oncology STLN Stock Holding History

Nuveen’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.65M Buy
1,408,720
+1,313,456
+1,379% +$5.52M ﹤0.01% 1864
2026
Q1 		$292K Buy
95,264
+18,592
+24% +$57K ﹤0.01% 3014
2025
Q4 		$273K Hold
76,672
– – ﹤0.01% 3067
2025
Q3 		$268K Hold
76,672
– – ﹤0.01% 3087
2025
Q2 		$157K Buy
+76,672
New +$192K ﹤0.01% 3201
2023
Q2 		– Sell
-52,343
Closed -$497K – 3291
2023
Q1 		$497K Hold
52,343
– – ﹤0.01% 2804
2022
Q4 		$497K Buy
52,343
+3,537
+7% +$9.93K ﹤0.01% 2885
2022
Q3 		$464K Buy
48,806
+22,337
+84% +$131K ﹤0.01% 2972
2022
Q2 		$251K Buy
+26,469
New +$193K ﹤0.01% 3126

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

Nuveen's STLN Position: Q2 2026 in Review

Nuveen increased its Starling Oncology (STLN) stake by 1,379% in Q2 2026, buying an estimated $5.52M and bringing the position to 1,408,720 shares worth $7.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1864.

Nuveen first reported a position in STLN in Q2 2022 and has held it in 9 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Nuveen held 1,408,720 shares of Starling Oncology worth $7.65M as of Q2 2026.
  • Nuveen bought 1,313,456 Starling Oncology shares in Q2 2026, an estimated $5.52M.
  • Starling Oncology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1864 holding.
  • Nuveen first reported a position in Starling Oncology in Q2 2022 and has held it in 9 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.